首页> 美国卫生研究院文献>Cancer Science >Targeting HOX/PBX dimer formation as a potential therapeutic option in esophageal squamous cell carcinoma
【2h】

Targeting HOX/PBX dimer formation as a potential therapeutic option in esophageal squamous cell carcinoma

机译:靶向HOX / PBX二聚体形成作为食管鳞状细胞癌的潜在治疗选择

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Homeobox genes are known to be classic examples of the intimate relationship between embryogenesis and tumorigenesis, which are a family of transcriptional factors involved in determining cell identity during early development, and also dysregulated in many malignancies. Previously, HOXB7, HOXC6 and HOXC8 were found abnormally upregulated in esophageal squamous cell carcinoma (ESCC) tissues compared with normal mucosa and seen as poor prognostic predictors for ESCC patients, and were shown to promote cell proliferation and anti‐apoptosis in ESCC cells. These three HOX members have a high level of functional redundancy, making it difficult to target a single HOX gene. The aim of the present study was to explore whether ESCC cells are sensitive to HXR9 disrupting the interaction between multiple HOX proteins and their cofactor PBX, which is required for HOX functions. ESCC cell lines (KYSE70, KYSE150, KYSE450) were treated with HXR9 or CXR9, and coimmunoprecipitation and immunofluorescent colocalization were carried out to observe HOX/PBX dimer formation. To further investigate whether HXR9 disrupts the HOX pro‐oncogenic function, CCK‐8 assay and colony formation assay were carried out. Apoptosis was assessed by flow cytometry, and tumor growth in vivo was investigated in a xenograft model. RNA‐seq was used to study the transcriptome of HXR9‐treated cells. Results showed that HXR9 blocked HOX/PBX interaction, leading to subsequent transcription alteration of their potential target genes, which are involved in JAK‐signal transducer and activator of transcription (STAT) activation and apoptosis inducement. Meanwhile, HXR9 showed an antitumor phenotype, such as inhibiting cell proliferation, inducing cell apoptosis and significantly retarding tumor growth. Therefore, it is suggested that targeting HOX/PBX may be a novel effective treatment for ESCC.
机译:同源异型盒基因被认为是胚胎发生与肿瘤发生之间密切关系的经典例子,它们是在早期发育过程中参与确定细胞身份的转录因子家族,在许多恶性肿瘤中也失调。以前,在食管鳞状细胞癌(ESCC)组织中发现HOXB7,HOXC6和HOXC8与正常粘膜相比异常上调,被认为是ESCC患者的不良预后指标,并被证明可以促进ESCC细胞的细胞增殖和抗凋亡。这三个HOX成员具有高水平的功能冗余,使得难以靶向单个HOX基因。本研究的目的是探索ESCC细胞是否对HXR9敏感,从而破坏了HOX功能所需的多种HOX蛋白与其辅因子PBX之间的相互作用。用HXR9或CXR9处理ESCC细胞系(KYSE70,KYSE150,KYSE450),并进行共免疫沉淀和免疫荧光共定位以观察HOX / PBX二聚体的形成。为了进一步研究HXR9是否破坏HOX致癌功能,进行了CCK-8测定和集落形成测定。通过流式细胞术评估细胞凋亡,并在异种移植模型中研究体内肿瘤的生长。 RNA-seq用于研究HXR9处理的细胞的转录组。结果表明,HXR9阻断了HOX / PBX的相互作用,导致其潜在靶基因的后续转录改变,这些靶基因参与JAK信号转导子和转录激活子(STAT)的激活以及细胞凋亡的诱导。同时,HXR9表现出抗肿瘤表型,例如抑制细胞增殖,诱导细胞凋亡并显着阻碍肿瘤生长。因此,建议靶向HOX / PBX可能是ESCC的新型有效治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号